The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).
Has a confirmed diagnosis of NMIBC based on TURBT or cold cup biopsy
Initiated first dose of TAR-200 in a real-world setting within 6 weeks prior to baseline visit/Study visit 1
Participants with childbearing potential are required to adhere to contraceptive recommendations as specified in the approved product labeling for TAR-200. Additionally, participants should seek consultation with their physician for personalized contraceptive advice
Must provide informed consent as described in the protocol
Has any medical condition deemed by the health care practitioner (HCP) as contraindicated to receive TAR-200 treatment
Had previous treatment with TAR-200 discontinued prior to baseline visit/Study visit 1
Previously received TAR-200 intravesically as part of a clinical trial(s)
Previously received greater than (>) 2 doses/cycles of TAR-200 in the real-world setting